Treatment patterns and clinical outcomes of patients with resectable non–small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World)
The Journal of Thoracic and Cardiovascular Surgery · 2024
DOI: 10.1016/j.jtcvs.2024.02.006 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2024. Verfasst von Zhenlin Yang und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Cancer Foundation of China, Ministry of Science and Technology of the People's Republic of China, Chinese Academy of Meteorological Sciences.
Abstract (Originalsprache)
BACKGROUND: Neoadjuvant immunotherapy has ushered in a new era of perioperative treatment for resectable non-small cell lung cancer (NSCLC). However, large-scale data for verifying the efficacy and optimizing the therapeutic strategies of neoadjuvant immunochemotherapy in routine clinical practice are scarce. METHODS: NeoR-World (NCT05974007) was a multicenter, retrospective cohort study involving patients who received neoadjuvant immunotherapy plus chemotherapy or chemotherapy alone in routine clinical practice from 11 medical centers in China between January 2010 and March 2022. Propensity score matching was performed to address indication bias. RESULTS: A total of 408 patients receiving neoadjuvant immunochemotherapy and 684 patients receiving neoadjuvant chemotherapy were included. The pathologic complete response (pCR) and major pathologic response (MPR) rates of the real-world neoadjuvant immunochemotherapy cohort were 32.8% and 58.1%, respectively. Notably, patients with squamous cell carcinoma exhibited significantly higher pCR and MPR rates than those with adenocarcinoma (pCR, 39.2% vs 16.5% [P < .001]; MPR, 66.6% vs 36.5% [P < .001]), whereas pCR and MPR rates were comparable among patients receiving different neoadjuvant cycles. In addition, the 2-year rates of disease-free survival (DFS) and overall survival (OS) rate were 82.0% and 93.1%, respectively. Multivariate analyses identified adjuvant therapy as an independent prognostic factor for DFS (hazard ratio [HR], 0.51; 95% confidence interval [CI], 0.29-0.89; P = .018) and OS (HR, 0.28; 95% CI, 0.13-0.58; P < .001). A significantly longer DFS with adjuvant therapy was observed in patients with non-pCR or 2 neoadjuvant cycles. We observed significant benefits in pCR rate (32.4% vs 6.4%; P < .001), DFS (HR, 0.50; 95% CI, 0.38-0.68; P < .001) and OS (HR, 0.61; 95% CI, 0.40-0.94; P = .024) with immunotherapy plus chemotherapy compared to chemotherapy alone both in the primary propensity-matched cohort and across most key subgroups. CONCLUSIONS: The study validates the superior efficacy of neoadjuvant immunochemotherapy over chemotherapy alone for NSCLC. Adjuvant therapy could prolong DFS in patients receiving neoadjuvant immunochemotherapy, and patients with non-pCR or those who underwent 2 neoadjuvant cycles were identified as potential beneficiaries of adjuvant therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Pathology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
- Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
- Department of Thoracic Surgery, Jining First People's Hospital, Jining, Shandong, China.
Förderung
- Cancer Foundation of China
- Ministry of Science and Technology of the People's Republic of China
- Chinese Academy of Meteorological Sciences
- Beijing Nova Program
- China Academy of Space Technology
- National Key Research and Development Program of China
Zitieren
APA
Yang, Z., Wang, S., Yang, H., Jiang, Y., Zhu, L., Zheng, B., Fu, H., Ma, J., Xie, H., Wang, Z., He, H., Xia, C., Li, R., Xu, J., Han, J., Huang, X., Li, Y., Zhao, B., Ni, C., …, & NeoR-World Research Group (2024). Treatment patterns and clinical outcomes of patients with resectable non–small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World). The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2024.02.006
Vancouver
Yang Z, Wang S, Yang H, Jiang Y, Zhu L, Zheng B, et al. Treatment patterns and clinical outcomes of patients with resectable non–small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World). The Journal of Thoracic and Cardiovascular Surgery. 2024. doi:10.1016/j.jtcvs.2024.02.006
BibTeX
@article{Yang2024,
author = {Yang, Zhenlin and Wang, Shuaibo and Yang, Haitang and Jiang, Yina and Zhu, Linhai and Zheng, Bin and Fu, Honghao and Ma, Junliang and Xie, Hounai and Wang, Zhiqiang and He, Huayu and Xia, Chuanbao and Li, Renda and Xu, Jiachen and Han, Jiefei and Huang, Xuhua and Li, Yixing and Zhao, Baicheng and Ni, Chenhui and Xing, Huajie and Chen, Yangtian and Wang, Jingdi and Jiang, Yuequan and Song, Yongxiang and Mao, Yousheng and Chen, Chun and Yao, Feng and Zhang, Guangjian and Hu, Jian and Xue, Qi and Gao, Shugeng and He, Jie and NeoR-World Research Group, NeoR-World Research Group},
title = {Treatment patterns and clinical outcomes of patients with resectable non–small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World)},
journal = {The Journal of Thoracic and Cardiovascular Surgery},
year = {2024},
doi = {10.1016/j.jtcvs.2024.02.006}
}
EUVIMED